Medopharm Private Limited
Indian Pharmaceutical Exporter · Antibiotics Specialist · $8.9M Total Trade · DGFT Verified
Medopharm Private Limited is an Indian pharmaceutical exporter with a total trade value of $8.9M across 6 products in 3 therapeutic categories. Based on 212 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Amoxicillin ($7.3M), Erythromycin ($500.0K), Flucloxacillin ($499.9K).
Medopharm Private Limited — Export Portfolio & Destination Treemap
Who is Medopharm Private Limited? — Company Overview & Market Position
Medopharm Private Limited, established on March 31, 1980, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of affordable medicines both domestically and internationally. Headquartered in Chennai, Tamil Nadu, India, the company operates under the Corporate Identification Number (CIN) U15100TN1980PTC008206. As of the latest available data, Medopharm has an authorized capital of ₹30.00 crore and a paid-up capital of ₹22.00 crore.
The company is part of the Chordia Group, a diversified conglomerate with an estimated valuation of $320 million, encompassing sectors such as pharmaceuticals, packaging, food, and distribution. Medopharm's product portfolio includes over 600 pharmaceutical products, with a significant focus on generic drugs, catering to more than 100 countries worldwide. The company employs approximately 6,500 individuals across its operations, reflecting its substantial presence in the pharmaceutical industry.
What Does Medopharm Private Limited Export? — Product Portfolio Analysis
Medopharm Private Limited Therapeutic Categories — 3 Specializations
Medopharm Private Limited operates across 3 therapeutic categories, with Antibiotics (86.6%), Antimalarial & Antiparasitic (7.8%), Advanced Antibiotics (5.6%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 98% of total exports.
Antibiotics
2 products · 86.6% · $7.8M
Antimalarial & Antiparasitic
3 products · 7.8% · $700.0K
Advanced Antibiotics
1 products · 5.6% · $499.9K
Product Portfolio — Top 6 by Export Value
Medopharm Private Limited exports 6 pharmaceutical products across 3 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Amoxicillin | Antibiotics | $7.3M | 145 | 1.2% | 9 |
| 2 | Erythromycin | Antibiotics | $500.0K | 10 | 0.6% | 8 |
| 3 | Flucloxacillin | Advanced Antibiotics | $499.9K | 25 | 1.3% | 10 |
| 4 | Pyrimethamine | Antimalarial & Antiparasitic | $262.7K | 14 | 0.6% | 10 |
| 5 | Sulfadoxine | Antimalarial & Antiparasitic | $262.7K | 14 | 0.5% | 8 |
| 6 | Praziquantel | Antimalarial & Antiparasitic | $174.6K | 4 | 6.0% | 2 |
Medopharm Private Limited exports 6 pharmaceutical products across 3 therapeutic categories with a total export value of $8.9M. The top category is Antibiotics (86.6% of portfolio), followed by Antimalarial & Antiparasitic (7.8%), indicating a concentrated portfolio with the top 5 products accounting for 98.0% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Need Detailed Data?
Shipment-level records, pricing & buyer contacts for Medopharm Private Limited.
Request DemoMedopharm Private Limited — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Medopharm Private Limited, established on March 31, 1980, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of affordable medicines both domestically and internationally. Headquartered in Chennai, Tamil Nadu, India, the company operates under the Corporate Identification Number (CIN) U15100TN1980PTC008206. As of the latest available data, Medopharm has an authorized capital of ₹30.00 crore and a paid-up capital of ₹22.00 crore.
The company is part of the Chordia Group, a diversified conglomerate with an estimated valuation of $320 million, encompassing sectors such as pharmaceuticals, packaging, food, and distribution. Medopharm's product portfolio includes over 600 pharmaceutical products, with a significant focus on generic drugs, catering to more than 100 countries worldwide. The company employs approximately 6,500 individuals across its operations, reflecting its substantial presence in the pharmaceutical industry.
2Manufacturing Facilities
Medopharm operates multiple manufacturing facilities in India, including a significant plant located in Guduvanchery, Tamil Nadu. This facility is approved by various regulatory agencies, such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA), adhering to Good Manufacturing Practice (GMP) standards. (cms.mhra.gov.uk) The plant specializes in the production of tablets, capsules, dry syrups, and oral suspensions, with a notable capability in beta-lactam antibiotics. Additionally, Medopharm has established offices and technological investments in countries like Sudan, Algeria, and Sri Lanka, indicating a strategic approach to global expansion.
3Key Leadership
Medopharm's leadership includes directors such as Hastimal Chordia, Balamurugan Rengasamy, and Tushar Chordia. Hastimal Chordia was appointed as a director on March 20, 2024, and has been associated with the company since November 1, 2019. Balamurugan Rengasamy and Tushar Chordia have been serving as directors since November 1, 2019. The company's leadership is committed to upholding the vision of its founder, the late Shri Mohanmulji Chordia, focusing on providing quality medicines at affordable costs.
Where Does Medopharm Private Limited Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Medopharm has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Guduvanchery, Tamil Nadu, has been inspected and approved by the UK's MHRA, confirming compliance with GMP standards. (cms.mhra.gov.uk) This approval facilitates the export of Medopharm's products to the UK and other European markets. While specific regulatory approvals for the U.S., Australia, and Japan are not detailed in the available sources, Medopharm's adherence to international GMP standards suggests potential market access in these regions.
2Emerging Markets
Medopharm has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's products are exported to over 100 countries, indicating a broad international footprint. Additionally, Medopharm's manufacturing facilities hold approvals from various regulatory agencies, such as the Ministry of Health in Sri Lanka and the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria, facilitating access to these markets.
3Geographic Strategy
Medopharm's geographic strategy demonstrates a strong diversification approach, with exports to over 100 countries across various continents. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the UK's MHRA, indicating a commitment to meeting global standards. (cms.mhra.gov.uk) This broad geographic presence mitigates concentration risk and positions Medopharm favorably in the global pharmaceutical market.
Medopharm Private Limited — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Specific details regarding Medopharm's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. However, the company's adherence to international GMP standards and approvals from other regulatory agencies suggest a potential pathway for FDA approvals. Medopharm's commitment to quality manufacturing practices positions it to meet the stringent requirements of the U.S. market.
2WHO & EU GMP
Medopharm's manufacturing facilities are approved by various regulatory agencies, including the UK's MHRA, confirming compliance with GMP standards. (cms.mhra.gov.uk) This approval facilitates the export of Medopharm's products to the UK and other European markets. While specific WHO prequalification and EU GMP certificates are not detailed in the available sources, the company's adherence to international GMP standards suggests potential compliance with these certifications.
3CDSCO & Indian Regulatory
Medopharm holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory standards. The company's manufacturing facilities are approved by various international regulatory bodies, including the UK's MHRA, indicating adherence to global standards. (cms.mhra.gov.uk) Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not available in the provided sources.
4Recent Regulatory Actions
Specific details regarding Form 483 observations, warning letters, or import alerts for Medopharm are not available in the provided sources. The company's adherence to international GMP standards and approvals from various regulatory agencies, including the UK's MHRA, suggests a strong compliance record. (cms.mhra.gov.uk)
Medopharm Private Limited — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Medopharm operates in a competitive pharmaceutical industry, with numerous companies offering similar products across various therapeutic categories. While specific market share comparisons are not available in the provided sources, Medopharm's extensive product portfolio and international presence position it as a significant player in the global market. The company's adherence to international GMP standards and approvals from various regulatory agencies, including the UK's MHRA, further enhance its competitive standing. (cms.mhra.gov.uk)
2Key Differentiators
Medopharm's key differentiators include its extensive experience of over five decades in pharmaceutical manufacturing, a diverse product portfolio of over 600 pharmaceutical products, and a significant international presence in more than 100 countries. The company's manufacturing facilities are approved by various regulatory agencies, including the UK's MHRA, confirming compliance with GMP standards. (cms.mhra.gov.uk) Additionally, Medopharm's strategic partnerships, such as the one with Tablets India Limited, enhance its market reach and product offerings.
3Strategic Position
Medopharm's current strategic direction focuses on expanding its global footprint by exporting affordable, high-quality medicines to over 100 countries. The company's adherence to international GMP standards and approvals from various regulatory agencies, including the UK's MHRA, positions it favorably in regulated markets. (cms.mhra.gov.uk) Future outlooks suggest continued growth through strategic partnerships and adherence to global standards, aiming to enhance its position in the global pharmaceutical market.
Buyer Due Diligence Brief — Evaluating Medopharm Private Limited as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Medopharm has a strong track record in pharmaceutical manufacturing, with over five decades of experience and a diverse product portfolio of over 600 pharmaceutical products. The company's manufacturing facilities are approved by various regulatory agencies, including the UK's MHRA, confirming compliance with GMP standards. (cms.mhra.gov.uk) Medopharm's products are exported to over 100 countries, indicating consistent export volume and reliability.
2Certifications to Verify
Importers should verify the following certifications when considering Medopharm as a supplier:
- FDA Registration: Confirm the company's FDA facility registrations and approved ANDAs through the FDA's official website.
- WHO-GMP Certification: Verify WHO-GMP certification through the World Health Organization's official website.
- EU GMP Certification: Check for EU GMP certification through the European Medicines Agency's official website.
- ISO Certification: Confirm ISO certifications through the International Organization for Standardization's official website.
Frequently Asked Questions — Medopharm Private Limited
How many pharmaceutical products does Medopharm Private Limited export from India?
Medopharm Private Limited exports 6 pharmaceutical products across 3 therapeutic categories. The top exports are Amoxicillin ($7.3M), Erythromycin ($500.0K), Flucloxacillin ($499.9K), Pyrimethamine ($262.7K), Sulfadoxine ($262.7K). Total export value is $8.9M.
What is Medopharm Private Limited's total pharmaceutical export value?
Medopharm Private Limited's total pharmaceutical export value is $8.9M, based on 212 verified shipments recorded in Indian Customs (DGFT) data.
What therapeutic categories does Medopharm Private Limited cover?
Medopharm Private Limited exports across 3 therapeutic categories. The largest are Antibiotics (86.6%, 2 products), Antimalarial & Antiparasitic (7.8%, 3 products), Advanced Antibiotics (5.6%, 1 products).
Get Full Medopharm Private Limited Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Medopharm Private Limited identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Medopharm Private Limited's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 212 individual customs records matching Medopharm Private Limited.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Products Tracked
3 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.